Nippon Chemiphar

Basic Information

Stock Code
4539
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
June 1950
Listing Year
October 1971
Official Website
https://www.chemiphar.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings, Daishin Chemical, TVE, Meiwa Industries

Overview

Nippon Chemiphar is a mid-sized pharmaceutical company founded in 1950 and headquartered in Chiyoda-ku, Tokyo. Its main business is manufacturing and selling pharmaceuticals, covering a wide range from new drug development to generic drugs.

Current Situation

Nippon Chemiphar recorded consolidated net sales of approximately 34.8 billion yen and ordinary income of approximately 1.5 billion yen in fiscal 2019, establishing a stable revenue base. Its mainstays are prescription pharmaceuticals and generic drugs, and it is actively shifting toward the generic drug market. Backed by its proprietary pharmaceutical manufacturing technology, it focuses on quality control and regulatory compliance, earning a certain level of trust within the pharmaceutical industry. In recent years, it has attempted overseas expansion through international partnerships and subsidiaries, though the domestic market remains central. For innovation, it continues investing in R&D while also advancing sophisticated manufacturing equipment. On the sustainability front, it promotes strengthened environmental and quality management, emphasizing socially responsible operations. Amid fierce competition with major pharmaceutical companies, it differentiates itself through specialization in generics and quality improvements. Going forward, it aims to reinvigorate new drug development and expand markets both domestically and internationally as mid- to long-term strategies. Expansion of health-related businesses and efficient import/export operations are also key priorities.

Trivia

Interesting Facts

  • Established in 1950, a long-established company with over 70 years of history.
  • Once used Koichi Morita's song 'Spin the Earth' in TV commercials.
  • Saki Fukuda served as image character for a period.
  • Has a history of receiving administrative sanctions for clinical data fabrication issues.
  • Owns subsidiary Nihon Yakuhin Kogyo for pharmaceutical manufacturing.
  • Focusing on the generic drug market to grow performance.
  • Holds a certain share in the clinical testing drug field.
  • Previously focused on new drug development but shifted emphasis to generics.
  • Changed from Tokyo Stock Exchange Second Section to First Section, then to Standard Market.
  • Expanding into health & medical related businesses for diversification.
  • Previously formed business alliance with India's Ranbaxy.
  • Strong domestic sales channels for prescription pharmaceuticals.
  • Provides rapid diagnostic products in testing drugs.
  • Headquartered in Iwamotocho, Chiyoda-ku, Tokyo.
  • Capital of approximately 4.3 billion yen, classified as mid-sized company.

Hidden Connections

  • Major shareholder Japan Sophal Shim is deeply involved in pharmaceutical manufacturing.
  • Collaborates with many related subsidiaries specialized in prescription pharmaceutical manufacturing.
  • Implemented market change in line with Tokyo Stock Exchange system revisions.
  • Once formed business tie-up with a major Indian pharmaceutical company to explore international expansion.
  • Generic drug manufacturing technology differentiates from domestic peers.
  • Diversified pharmaceutical-related businesses through testing drug operations.
  • Quality management strengthening rooted as organizational culture from past quality incident experience.
  • Health & medical related business watched as future growth area.

Future Outlook

Growth Drivers

  • Expansion of generic drug market
  • Increasing medical needs from aging society
  • Stricter domestic and international pharmaceutical regulations emphasizing quality
  • Manufacturing efficiency improvements through technological innovation
  • New demand creation in health-related businesses
  • Strengthened relationships with domestic medical institutions
  • Increasing demand for rapid diagnostics in clinical testing drugs
  • Expansion of import/export business internationally
  • Enhanced response to environment & sustainability
  • Increasing needs for combination drugs due to polypharmacy
  • Business efficiency via ICT utilization

Strategic Goals

  • 50% increase in generic drug sales
  • Achieve domestic market share expansion
  • Early initiation of clinical development for new drug candidates
  • 30% reduction in manufacturing environmental impact
  • Expansion of clinical testing drug lineup and new product launches
  • Promotion of diversification in healthcare-related services
  • Strengthening sales channels domestically and internationally
  • Realization of sustainable pharmaceutical manufacturing
  • Establishment and maintenance of advanced quality management system
  • Expansion of overseas partnership alliances

Business Segments

Manufacturing and Sales of Prescription Pharmaceuticals

Overview
Business of manufacturing and supplying high-quality pharmaceuticals to medical institutions.
Competitiveness
Strict quality control and stable supply system
Customers
  • Hospitals
  • Clinics
  • Pharmacies
  • Medical institutions
  • Pharmaceutical wholesalers
Products
  • Antibiotics
  • Gastrointestinal therapeutics
  • Analgesics
  • Anti-allergy drugs
  • Diabetes therapeutics

Generic Drug Business

Overview
Manufacturing and sales of generic drugs provided at low prices with quality equivalent to originals.
Competitiveness
Cost competitiveness and high quality standards
Customers
  • Pharmacies
  • Hospitals
  • Generic drug distributors
Products
  • Generic antibacterials
  • Generic gastrointestinal drugs
  • Generic analgesics

Clinical Testing Drugs

Overview
Manufactures and sells testing drugs for medical sites.
Competitiveness
Rapid and accurate testing technology
Customers
  • Hospital testing departments
  • Clinics
  • Testing centers
Products
  • Blood glucose measurement kits
  • Infectious disease rapid test drugs
  • Clinical diagnostic supplies

Import/Export Operations

Overview
Handles import/export and international transactions of pharmaceutical-related products.
Competitiveness
Global network and regulatory compliance
Customers
  • Overseas pharmaceutical sales agents
  • Exporters
  • Importers
Products
  • Pharmaceutical raw materials
  • Finished pharmaceuticals
  • Testing equipment

Health & Medical Related Business

Overview
Provision and services of related medical supplies and health products.
Competitiveness
Diverse product lineup and service integration
Customers
  • Medical institutions
  • Welfare facilities
  • Health checkup centers
Products
  • Pharmaceutical accessories
  • Health supplements
  • Medical device accessories

Competitive Advantage

Strengths

  • Abundant pharmaceutical manufacturing experience
  • Strict quality management system
  • Expertise in generic drug development
  • Diverse product lineup
  • Strong domestic distribution network
  • Rapid regulatory compliance response
  • Stable financial base
  • Business diversification through subsidiaries
  • Robust R&D structure
  • Long-term market trust
  • Product improvements aligned with market needs
  • Experienced management team
  • Reliable testing drug supply
  • Close relationships with medical institutions
  • Established import/export system

Competitive Advantages

  • Cost competitiveness and quality balance in generic drugs
  • Accumulated manufacturing know-how in prescription pharmaceuticals
  • Rapid product development in clinical testing drugs
  • Strong domestic market presence with multiple sales channels
  • Synergy effects from parent-subsidiary collaborations
  • Flexible development adapting to regulatory changes
  • Long-term trust relationships with domestic and international medical institutions
  • Aggressive marketing for market share expansion
  • CM strategy to enhance brand image
  • Broad product range from new drugs to generics
  • Strengthened quality assurance system
  • Stable raw material procurement network
  • Effective internal R&D investments
  • Wide range of pharmaceutical-related services
  • Diversified expansion into health & medical businesses

Threats

  • Intense price competition with major pharmaceutical companies
  • Increased development costs from stricter regulations
  • Price pressures in the generic drug market
  • Complications from pharmaceutical patent issues
  • Risks in overseas business expansion
  • Raw material price fluctuation risks
  • Increase in new market entrants
  • Impacts from healthcare system reforms
  • Brand damage from quality issues
  • Currency fluctuation effects
  • Domestic market shrinkage due to population decline
  • Delays in responding to technological innovations

Innovations

2024: Generic Drug Quality Improvement Project

Overview
Initiated initiatives to enhance generic drug quality by introducing the latest manufacturing technologies.
Impact
Contributes to market share expansion and improved customer satisfaction

2023: Rapid Diagnostic Technology Development for Clinical Testing Drugs

Overview
Successfully developed new testing drugs capable of rapid infectious disease diagnosis.
Impact
Contributes to improved diagnostic efficiency in medical settings

2022: AI-Utilized Manufacturing Process Optimization

Overview
Introduced AI technology-based production line efficiency project.
Impact
Achieved productivity improvements and cost reductions

2021: Basic R&D for New Diabetes Treatment Drug

Overview
Expanded basic research on diabetes treatment drug candidate with novel mechanism of action.
Impact
Foundation for future new drug launch

2020: Introduction of Low-Environmental-Impact Manufacturing Equipment

Overview
Installed energy-saving and resource-efficient manufacturing equipment at domestic factories.
Impact
Reduced CO2 emissions by 15% annually

Sustainability

  • Reducing environmental impact in pharmaceutical manufacturing processes
  • Promoting introduction of energy-saving equipment
  • Improving waste recycling rate
  • Strengthening and transparizing quality management system
  • Contributing to local environmental protection
  • Ensuring employee health and safety
  • Ensuring proper supply and safety of pharmaceuticals
  • Sustainable resource procurement
  • Thorough compliance adherence
  • Initiatives to improve customer satisfaction
  • Educational support for medical professionals
  • Strengthening IT system security